REGENERON - A Myriad of Opportunities - EYLEA (AMD, CRVO) + ZALTRAP (mCRC) + ARCALYST (Gout)
An exceptional sales of EYLEA (VEGF Trap-Eye, L in US, partnered with Bayer for Ex-US, wet AMD) - $124m in 1Q12 and ~$150m since its approval (in Nov. ’11) reflects a market share of 12% of treatment-naïve pts and ~10% of the anti-VEGFs (Lucentis, Avastin) market. We expect the favorable sales trajectory to continue on the back of further market share gain and label expansion in CRVO (central retinal vein occlusion, PDUFA: Sept. 23, 2012). Besides Eylea, approvals of ZALTRAP (R, for mCRC, PDUFA: Aug. 4, 2012) and ARCALYST (R, for prevention of gout flares, PDUFA: July 30, 2012) should boost growth and revenues. REGN’s Evergreen Asset –Biologics focused technology platform, 10 monoclonal antibodies in early- to mid-stage development besides the launched and late stage pipeline continue to hold investors’ interest! To know more about marketed and pipeline potential, please read our report, released on May 1, 2012 on REGN, titled “A Myriad of Opportunities – EYLEA (AMD, CRVO) + ZALTRAP (mCRC) + ARCALYST (Gout)”.
COMPANIES MENTIONED
REGENERON
REGENERON
